ORILIGAL CAP is an effective anti-obesity medication containing Orlistat, used for the management of weight loss in obese individuals. It works by inhibiting fat absorption in the intestine, thereby reducing calorie intake and supporting a structured weight management plan. Manufactured under WHO-GMP certified facilities by Bluepill Express, ORILIGAL CAP is designed for both domestic and international pharmaceutical markets requiring consistent, high-quality weight loss solutions.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

ORILIGAL CAP is a potent pharmaceutical preparation containing Orlistat, primarily indicated for the management of obesity in adults and adolescents. It is specifically formulated to support medically supervised weight reduction programs, helping individuals achieve and maintain a healthier body weight. Orlistat, the active pharmaceutical ingredient in ORILIGAL CAP, functions by selectively inhibiting gastrointestinal lipases, the enzymes responsible for breaking down dietary fat. By blocking the absorption of nearly 30% of dietary fat consumed, ORILIGAL significantly reduces overall caloric intake without altering appetite.

This mechanism not only supports steady weight loss but also contributes to improved metabolic health outcomes such as better glycemic control, lower cholesterol levels, and reduced blood pressure in overweight individuals. ORILIGAL CAP is commonly prescribed as an adjunct to a hypocaloric diet and regular physical activity. It is particularly beneficial for patients with conditions linked to excess weight, including type 2 diabetes, dyslipidemia, and hypertension.

Manufactured by Bluepill Express under stringent pharmaceutical guidelines, ORILIGAL CAP adheres to internationally recognized quality standards such as WHO-GMP, ISO, and regulatory accreditations relevant to major global markets including the United States, Europe, Africa, Southeast Asia, and Latin America. The manufacturing process involves precise API validation, moisture-sensitive encapsulation, and stability-controlled packaging to ensure long-term potency and safety.

ORILIGAL CAP is typically available in dosages such as 60 mg and 120 mg, and may be customized for bulk export, institutional supply, or private labeling needs. The formulation does not affect the central nervous system and does not interfere with cardiovascular function, making it a safer alternative to stimulant-based weight loss medications. While effective, it is also well-tolerated, with the most common side effects being gastrointestinal in nature and generally manageable with dietary modifications.

In addition to the therapeutic benefits, ORILIGAL also plays a preventive role in reducing the risk of obesity-related diseases when used responsibly under professional guidance. Bluepill Express offers full technical documentation, including Certificate of Analysis, stability data, and dossier support, making the product fully compliant for regulatory submissions and pharmacy distribution worldwide.

ORILIGAL CAP is packaged in tamper-proof blister strips or HDPE bottles with patient instructions and label customization available in multiple languages. The capsules are manufactured with pharmaceutical-grade excipients and gelatin-free options can be developed to meet vegetarian or vegan consumer preferences.